Serotypes of Streptococcus pneumoniae Isolates from Children with Invasive Pneumococcal Disease in Turkey: Baseline Evaluation of the Introduction of the Pneumococcal Conjugate Vaccine Nationwide

ABSTRACT Before use of the pneumococcal conjugate vaccine PCV7 became widespread in Turkey, 202 invasive pneumococcus isolates were analyzed. The most common serotypes were 19F and 6B. In children ≤2 years of age, the potential coverage rate of PCV7 was 69.5%. The most frequent non-PCV7 serotypes were 19A, 3, 1, 6A, and 8.

Streptococcus pneumoniae (pneumococcus) is the leading cause of severe pneumonia in children across the world (26). The World Health Organization (WHO) estimates that about 700,000 to 1 million children die of pneumococcal disease every year, most of whom are young children in developing countries (30). In 2007, WHO recommended that pneumococcal conjugate vaccine PCV7 be included in national immunization programs (NIP) (30). As of May 2009, PCV7 was licensed in over 90 countries and included in the NIP of 36 countries worldwide, including Turkey (24). PCV7 currently represents the only PCV with proven global effectiveness against invasive pneumococcal disease (IPD) (1,5,8,20,22,29). Recently, two more PCVs have been introduced; PCV10 covers serotypes 1, 5, and 7F in addition to the PCV7 serotypes, and PCV13 covers serotypes 3, 6A, and 19A in addition to the PCV10 serotypes (14).
The percentage of circulating serotypes causing IPD that are covered by PCV7 ranged from 60% to 80% for European children Ͻ2 years of age (15). In the United States, population-based and laboratory-based surveillance data indicated that overall IPD rates among children Ͻ5 years of age were 77% lower (approximately 13,000 fewer cases) in 2005 than in the years prior to introduction of the vaccine (1998 to 1999) (2).
In a study conducted in Turkey between the years 2001 and 2004, the proportion of potentially preventable cases was found to be the highest (63%) in the age group of 0 to 24 months (31). From November 2008, PCV7 has been included in the NIP in Turkey for children aged Ͻ2 years (17). Widescale use of PCV7 has been shown to change the circulating serotypes in a population, and nonvaccine serotypes like 19A appear in a higher percentage of the remaining viral burden that can cause IPD (16,20,23,28). Therefore, surveillance of pneumococcal diseases on the basis of serotypes is essential, not only to learn about the current serotype pattern but also to observe the effectiveness of PCVs by following possible serotype changes in the population after vaccine introduction. In several studies, regional and temporal variations in serotype distribution were reported after PCV usage (6,7,(10)(11)(12). In this study, we aimed to identify serotypes of pneumococcal strains causing IPD in children in Turkey during the time period when PCV7 was newly included in the country's NIP.
S. pneumoniae strains were consecutively isolated at 15 different health centers in Turkey, serving about 55% of the country's population, between July 2008 and February 2010. Approval was obtained from the ethics committee of the coordinator center, in accordance with local regulations. The pneumococci were isolated as a part of the routine clinical diagnostic practice, from blood, cerebrospinal fluid, and other body fluids of pediatric cases (Յ18 years) with IPD. Penicillin susceptibility testing was performed according to the guidelines of the Clinical and Laboratory Standards Institute (3). Serotyping was performed by the Quellung reaction using serotype-specific antisera (Statens Seruminstitut, Copenhagen, Denmark).
Of 202 invasive isolates, 68 (33.7%) were penicillin nonsusceptible (PNS). Of these PNS isolates, 66.2% (n ϭ 45) were from children Յ2 years of age. The proportions of PNS isolates potentially covered by the PCV7, PCV10, and PCV13 vaccines were 77.8%, 82.2%, and 91.1%, respectively, in the first 2 years of age. The proportion of PNS isolates in children was approximately 11% in Western Europe countries, with the highest proportion (49%) in Spain and the lowest proportion (Ͻ1%) in Germany (13). This proportion is about 50% in Egypt and 44% in Saudi Arabia (9).
Our results suggest that the incidence of pneumococcal diseases can be decreased by widespread use of the vaccine in Turkey due to the fact that the potential PCV7 coverage rate is approximately 70% in patients Յ2 years of age, the target population for vaccination. However, gradual serotype replacement is another global fact seen with PCV7 NIP. In the   FIG. 1. Vaccine coverage rates for PCV7, PCV10, and PCV13 by age group. United States, the total IPD burden, which has significantly been decreased by PCV7, seems to have reached a plateau due to the gradual increase of the non-PCV7 serotypes, mainly 19A (20). Similar changes were also reported from European countries after the introduction of PCV7 (27). Greece, a neighboring country running an NIP for PCV7, has also reported 19A as the leading non-PCV7 serotype (V. Syriopoulou et al., Paediatric pneumococcal serotype epidemiology after the introduction of the heptavalent conjugated vaccine in Greece: an interim analysis, poster 261, presented at World Society for Pediatric Infectious Diseases, 2009). In our study, serotypes 19A and 3 were the most frequent non-PCV7 serotypes, totaling almost 10%. Thus, our results appear to show a potential background for a similar serotype replacement due to the national PCV7 vaccination in Turkey. Penicillin has been universally effective in treating IPD, but the emergence of resistant strains is causing problems (18,21). The prevalence of PNS pneumococci appears to be on the rise in Turkey (25). Our results showed that most of the PNS strains (66.2%) were isolated from patients Յ2 years old and PCV7 vaccination led to a considerable coverage in PNS IPD isolates (77.8% for the Յ2-year age group). With the PCV7 NIP, we may now have a considerable decrease in PNS IPD cases in Turkey, as has previously been seen in the United States and in Europe (4,15).
We believe that ongoing surveillance of pneumococcal diseases is essential to closely monitor the disease dynamics after routine use of PCV7 or the other PCVs. This study was supported by an unrestricted research grant, 0887X1-4439, from Wyeth-Turkey.